Onkologie. 2023:17(4):241-245 | DOI: 10.36290/xon.2023.046

Treatment of metastatic colorectal carcinoma - 3rd line and above

Pavel Pacas, Adam Lukáč
Onkologická klinika, 2. LF UK a FN Motol, Praha

Terapeutic possbilities in mCRC in 3rd and higher line of treatment are constantly expanding not only by new combinations of actual treatment possibilities, but also by discoveries of new small targeted molecules. Results of clinical studies prove that by right therapeutic intervention, we can prolong lives of highly pre-treated patients without worsening their quality of life. Ever evolving clinical oncology require us to have constant knowledge of actual therapeutic regimes and formation of new approach in higher lines of treatment in advanced illness.

Keywords: trifluridin-tipiracil, regorafenim, new combinations of actual treatment possibilities mCRC, new targeted molecules, panitumumab, anti-HER2 therapy, fruquintinib.

Accepted: October 3, 2023; Published: October 5, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pacas P, Lukáč A. Treatment of metastatic colorectal carcinoma - 3rd line and above. Onkologie. 2023;17(4):241-245. doi: 10.36290/xon.2023.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Souhrn údajů o přípravku, SPC [Internet] [cited 9. 5. 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_cs.pdf.
    2. ClinicalTrials TAS-102, Trifluritin/tipiracil [Internet] 2015, [cit. 28.12.2015]. Available from: https://clinicaltrials.gov/ct2/results?term=TAS-102&Search=Search.
    3. Lonsurf, Efficacy overall survival data, [Internet], [cited 2/2019]. Available from: https://www.lonsurfhcp.com/mcrc-treatment/efficacy.
    4. Souhrn údajů o přípravku, SPC [Internet], [cited 10. 12. 2020]. Available from: https://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf.
    5. ClinicalTrials NCT01103323, Regorafenib [Internet] 2015, [cited 24.6.2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01103323.
    6. Obermannova S, Grell P, Dvorak J, et al. TAS-102 in metastatic colorectal cancer (mCRC) - predictive and prognostic factors in a European patient population. Japanese Society of Medical Oncology (JSMO). Annual meeting; 2018. Abstract P2-088. Go to original source...
    7. Kopečková K, Buchler T, Bortlíček Z, et al. Regorafenib in the real-life clinical practice: data from Czech Registry. Target Oncol. 2017;12:89-95. Go to original source... Go to PubMed...
    8. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-1919. Go to original source... Go to PubMed...
    9. Tabernero J, Taieb J, Prager G, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol. 2021;17(16):1977-1985. Available from: https://www.futuremedicine.com/doi/full/10.2217/fon-2020-1238. Last accessed: January 2023. Go to original source... Go to PubMed...
    10. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine. 2023;388(18):1657-1667. Go to original source... Go to PubMed...
    11. Napolitano S, De Falco V, Martini G, et al. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023; online May 18. doi:10.1001/jamaoncol.2023.0655. Go to original source... Go to PubMed...
    12. Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1. PMID: 35915157; PMCID: PMC9386661. Go to original source... Go to PubMed...
    13. Li J, Qin S, Xu RH, Shen L, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486. Go to original source... Go to PubMed...
    14. Xu X, Yu Y, Liu M, et al. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. Transl Cancer Res. 2022;11(1):276-287. doi: 10.21037/tcr-20-3539. PMID: 35261903; PMCID: PMC8841594. Go to original source... Go to PubMed...
    15. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. The Lancet Oncology. 2023;24(5):496-508. Go to original source... Go to PubMed...
    16. Takayuki Y, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nature Communications. 2023;14(1):3332. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.